lilly glp-1 drugs drug analogs, new trend in obesity treatment, become even more effective < Pharma < Article Eli Lilly Weight-Loss Pill Shows – As GLP-1 Use Expands, Long-Term

CCK8, D-Hanks and Rhodamine 123 were purchased from Solarbio (Beijing, China)

American Medical Association: What Doctors Want Patients to Know About Anti-Obesity Medication Harvard Health Publishing: GLP-1 Diabetes and Weight-Loss Drug Side Effects U.S

The administration of cagrilintide, an extended-release amylin analog, in combination with semaglutide has shown average weight loss of 22.7% after 68 weeks of treatment in obese subjects compared to 15.7% weight loss with semaglutide alone, marking a 44% increase in weight loss efficacy compared to monotherapy, and putting it into a category of bariatric surgery alternatives

95% CI 1.2325.22